ATRC · Insider Trading
AtriCure, Inc.
Every open-market purchase and sale reported by ATRC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-24 | Salvatore Privitera | Chief Technical Officer | Sell | −4,519 | −$271.14K |
| 2026-09-14 | Regina E Groves | Director | Sell | −5,313 | −$288.07K |
| 2026-09-10 | Salvatore Privitera | Chief Technical Officer | Sell | −3,657 | −$201.13K |
| 2026-09-04 | Salvatore Privitera | Chief Technical Officer | Sell | −7,763 | −$407.56K |
| 2026-08-26 | Karl S. Dahlquist | Chief Legal Officer | Sell | −9,370 | −$458.10K |
| 2026-08-07 | Maggie Yuen | Director | Sell | −3,500 | −$134.47K |
| 2026-08-07 | Karen Prange | Director | Sell | −3,564 | −$138.28K |
| 2026-08-07 | Karen Prange | Director | Sell | −3,564 | −$138.28K |
| 2026-08-07 | Maggie Yuen | Director | Sell | −3,500 | −$134.47K |
| 2026-08-03 | Michael H Carrel | President, CEO, & Director | G | −4,700 | — |
| 2026-07-30 | Justin J Noznesky | Chief Mktg & Strategy Officer | Sell | −6,182 | −$239.86K |
| 2026-07-30 | Vinayak Doraiswamy | Chief Scientific Officer | Sell | −6,000 | −$233.28K |
| 2026-07-30 | Sven Wehrwein | Director | MIXED | — | −$447.25K |
| 2026-07-02 | Salvatore Privitera | Chief Technical Officer | A | +636 | +$15.12K |
| 2026-07-02 | Karl S. Dahlquist | Chief Legal Officer | A | +636 | +$15.12K |
| 2026-07-02 | Vinayak Doraiswamy | Chief Scientific Officer | A | +636 | +$15.12K |
| 2026-07-02 | Michael H Carrel | President, CEO, & Director | A | +636 | +$15.12K |
| 2026-07-02 | Douglas J Seith | Chief Operating Officer | A | +527 | +$12.53K |
| 2026-05-22 | Karen Prange | Director | Sell | −3,000 | −$85.95K |
| 2026-05-20 | Deborah H Telman | Director | A | +6,144 | — |
| 2026-05-20 | Robert S. White | Director | A | +6,144 | — |
| 2026-05-20 | Regina E Groves | Director | A | +6,144 | — |
| 2026-05-20 | Shlomo Nachman | Director | A | +6,144 | — |
| 2026-05-20 | Sven Wehrwein | Director | A | +6,144 | — |
| 2026-05-20 | Maggie Yuen | Director | A | +6,144 | — |
| 2026-05-20 | B Kristine Johnson | Director | A | +6,144 | — |
| 2026-05-20 | Karen Prange | Director | A | +6,144 | — |
| 2026-05-18 | Vinayak Doraiswamy | Chief Scientific Officer | Sell | −5,000 | −$140.65K |
| 2026-03-16 | Vinayak Doraiswamy | Chief Scientific Officer | Sell | −5,000 | −$149.15K |
| 2026-03-12 | Robert S. White | Director | M | +10,000 | +$149.90K |
| 2026-03-09 | Michael H Carrel | President, CEO, & Director | G | −6,000 | — |
| 2026-03-03 | Douglas J Seith | Chief Operating Officer | MIXED | +44,970 | −$717.35K |
| 2026-03-03 | Vinayak Doraiswamy | Chief Scientific Officer | MIXED | +30,003 | −$487.19K |
| 2026-03-03 | Salvatore Privitera | Chief Technical Officer | MIXED | +32,461 | −$410.35K |
| 2026-03-03 | Angela L Wirick | Chief Financial Officer | MIXED | +40,123 | −$717.89K |
| 2026-03-03 | Karl S. Dahlquist | Chief Legal Officer | MIXED | +27,502 | −$490.38K |
| 2026-03-03 | Justin J Noznesky | Chief Mktg & Strategy Officer | MIXED | +27,603 | −$487.22K |
| 2026-03-03 | Michael H Carrel | President, CEO, & Director | MIXED | +97,121 | −$2.28M |
| 2026-01-02 | Douglas J Seith | Chief Operating Officer | A | +257 | +$7.03K |
| 2025-12-12 | Michael H Carrel | President, CEO, & Director | G | −4,000 | — |
| 2025-11-26 | Justin J Noznesky | Chief Mktg & Strategy Officer | Sell | −5,166 | −$192.64K |
| 2025-11-26 | Sven Wehrwein | Director | MIXED | — | −$177.08K |
| 2025-11-25 | Maggie Yuen | Director | Sell | −3,000 | −$107.16K |
| 2025-11-17 | Michael H Carrel | President, CEO, & Director | G | −6,000 | — |
| 2025-09-16 | Justin J Noznesky | Chief Mktg & Strategy Officer | Sell | −3,000 | −$108.90K |
| 2025-08-26 | Sven Wehrwein | Director | MIXED | — | −$85.25K |
| 2025-08-21 | Sven Wehrwein | Director | MIXED | — | −$80.25K |
| 2025-08-12 | Michael H Carrel | President, CEO, & Director | G | −10,000 | — |
| 2025-08-08 | Regina E Groves | Director | Sell | −2,452 | −$90.28K |
| 2025-08-07 | Vinayak Doraiswamy | Chief Scientific Officer | Sell | −2,500 | −$91.45K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael H Carrel | President, CEO, & Director | 792,744 | $48.56M |
| Douglas J Seith | Chief Operating Officer | 229,867 | $14.08M |
| Angela L Wirick | Chief Financial Officer | 227,858 | $13.96M |
| Salvatore Privitera | Chief Technical Officer | 142,745 | $8.74M |
| Robert S. White | Director | 128,318 | $7.86M |
| Justin J Noznesky | Chief Mktg & Strategy Officer | 100,219 | $6.14M |
| Karl S. Dahlquist | Chief Legal Officer | 87,319 | $5.35M |
| Vinayak Doraiswamy | Chief Scientific Officer | 86,511 | $5.30M |
| Sven Wehrwein | Director | 65,518 | $4.01M |
| B Kristine Johnson | Director | 55,954 | $3.43M |
| Deborah Lee Yount | Chief Human Resources Officer | 45,578 | $2.79M |
| Regina E Groves | Director | 34,546 | $2.12M |
| Deborah H Telman | Director | 28,328 | $1.74M |
| Shlomo Nachman | Director | 24,655 | $1.51M |
| Karen Prange | Director | 22,809 | $1.40M |
| Maggie Yuen | Director | 14,015 | $858.42K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ATRC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.